National Cancer Institute (NCI)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).

3,257 total trials 326 currently recruiting 2051 completed early-phase tilt top decile by trial count

National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.

National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.

Top-decile sponsor footprint

National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

3,257 total, page 15 of 66

ACTIVE NOT RECRUITING Phase 3

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037
ACTIVE NOT RECRUITING Phase 1

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

NCT01303341
ACTIVE NOT RECRUITING Phase 1

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT01281176
ACTIVE NOT RECRUITING Phase 3

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NCT01169337
ACTIVE NOT RECRUITING

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes

NCT01200680
ACTIVE NOT RECRUITING Phase 2

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT01134614
ACTIVE NOT RECRUITING Phase 2

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

NCT01251861
ACTIVE NOT RECRUITING Phase 1

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

NCT01251874
ACTIVE NOT RECRUITING Phase 1

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00972478
ACTIVE NOT RECRUITING Phase 3

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

NCT01081262
ACTIVE NOT RECRUITING Phase 2

Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

NCT01176006
ACTIVE NOT RECRUITING Phase 3

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01167712
ACTIVE NOT RECRUITING Phase 2

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT01142388
ACTIVE NOT RECRUITING Phase 1

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

NCT01089101
ACTIVE NOT RECRUITING Phase 2

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

NCT01059786
ACTIVE NOT RECRUITING Phase 1

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

NCT01116648
ACTIVE NOT RECRUITING Phase 1

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

NCT01064648
ACTIVE NOT RECRUITING Phase 1

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

NCT00669734
ACTIVE NOT RECRUITING Phase 1

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

NCT01012817
ACTIVE NOT RECRUITING Phase 1

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

NCT01038778
ACTIVE NOT RECRUITING Phase 3

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

NCT00980460
ACTIVE NOT RECRUITING Phase 2

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT00977574
ACTIVE NOT RECRUITING Phase 2

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

NCT00792948
ACTIVE NOT RECRUITING Phase 2

Dinaciclib in Treating Patients With Stage IV Melanoma

NCT00937937
ACTIVE NOT RECRUITING Phase 1

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

NCT00878163
ACTIVE NOT RECRUITING Phase 3

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

NCT00843882
ACTIVE NOT RECRUITING Phase 2

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00658814
ACTIVE NOT RECRUITING Phase 2

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

NCT00923013
ACTIVE NOT RECRUITING Phase 1

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

NCT00740805
ACTIVE NOT RECRUITING Phase 3

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT00588770
ACTIVE NOT RECRUITING Phase 3

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

NCT00644228
ACTIVE NOT RECRUITING Phase 3

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00602641
ACTIVE NOT RECRUITING

Natural History Study of Patients With Neurofibromatosis Type I

NCT00924196
ACTIVE NOT RECRUITING Phase 3

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00565851
ACTIVE NOT RECRUITING Phase 3

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

NCT00569127
ACTIVE NOT RECRUITING Phase 3

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

NCT00433511
ACTIVE NOT RECRUITING Phase 1

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT00392353
ACTIVE NOT RECRUITING Phase 1

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

NCT00365157
ACTIVE NOT RECRUITING Phase 2

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00334815
ACTIVE NOT RECRUITING Phase 3

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

NCT00310180
ACTIVE NOT RECRUITING Phase 1

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

NCT00336063
ACTIVE NOT RECRUITING Phase 1

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

NCT00268385
ACTIVE NOT RECRUITING Phase 2

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

NCT00265798
ACTIVE NOT RECRUITING Phase 3

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

NCT00217737
ACTIVE NOT RECRUITING Phase 3

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

NCT00114101
ACTIVE NOT RECRUITING Phase 3

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

NCT00098475
ACTIVE NOT RECRUITING Phase 2

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

NCT00092222
ACTIVE NOT RECRUITING Phase 2

Decitabine in Treating Patients With Myelofibrosis

NCT00095784
ACTIVE NOT RECRUITING Phase 2

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

NCT00070499
ACTIVE NOT RECRUITING

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

NCT00039676
← Previous Page 15 of 66 Next →

Phase Distribution

PhaseTrial count
Phase 1 1199
Phase 2 1429
Phase 3 193

Therapeutic Areas

Advanced Malignant Solid Neoplasm 67
Refractory Malignant Solid Neoplasm 45
Metastatic Malignant Solid Neoplasm 38
Refractory Multiple Myeloma 35
Prostate Cancer 34
Refractory Lymphoma 33
Advanced Lymphoma 33
Acute Myeloid Leukemia 28
Unspecified Adult Solid Tumor, Protocol Specific 26
Breast Cancer 23

What is open in the National Cancer Institute (NCI) pipeline

326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).

Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).

Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.